You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 36 No. 5, May 1979 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Blood Levels of Neuroleptic Drugs in Nonresponding Chronic Schizophrenic Patients

Robert C. Smith, MD, PhD; John Crayton, MD; Haroutune Dekirmenjian, PhD; Davis Klass, MD; John M. Davis, MD

Arch Gen Psychiatry. 1979;36(5):579-584.


Abstract

• Blood levels of butaperazine were measured in scmzophrenic patients who were chronic nonresponders to their psychotropic medication. The blood levels were compared with those in patients who had shown a better clinical response to this neuroleptic. Nonresponders had two to seven times lower levels of butaperazine in plasma and RBCs after a single dose or chronic dosing. Some of the patients later treated with thioridazine or haloperidol had lower plasma levels of these neuroleptics also. No significant differences were found between nonresponders and relative responders in either the a- or ;,2;-phase half-life of butaperazine in plasma and RBCs after administration of a single dose of the drug. Butaperazine and thioridazine levels were not related to previously administered amounts of neuroleptic drugs. These findings do not support the hypothesis that low blood levels are the result of faster systemic metabolism of the drug after it reaches the central circulation. Our results suggest that low blood levels of neuroleptics may be one important factor in the poor clinical response of some chronic schizophrenic patients.



Author Affiliations

From the Departments of Psychiatry, University of Chicago (Drs Smith, Crayton, Dekirmenjian, and Davis) and Manteno (Ill) Mental Health Center (Drs Smith, Crayton, and Klass); and the Illinois State Psychiatric Institute, Chicago (Drs Davis and Dekirmenjian). Dr Smith is now chief, Section of Behavioral Neurochemistry, Texas Research Institute of Mental Sciences, Houston.


Footnotes

Accepted for publication Sept 5, 1978.

Reprint requests to Behavioral Neurochemistry, Texas Research Institute of Mental Sciences, 1300 Moursund, Texas Medical Center, Houston, TX 77030 (Dr Smith).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients
Browne et al.
J Psychopharmacol 1988;2:94-103.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Progress in Pharmacotherapy of Borderline Disorders: A Double-blind Study of Amitriptyline, Haloperidol, and Placebo
Soloff et al.
Arch Gen Psychiatry 1986;43:691-697.
ABSTRACT  

Low Serum Neuroleptic Levels Predict Relapse in Schizophrenic Patients
Brown et al.
Arch Gen Psychiatry 1982;39:998-1000.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1979 American Medical Association. All Rights Reserved.